Tislelizumab,Sorafenib
BeiGene,Novartis
['tisle ']
 bclc c 67.9%, extrahepatic disease 54.5% in tisle group, os in general population not much different, but in sub group &gt; 65 yes. i understand your point professor but 54 % no candidates for looking r0
Hepatopancreatobiliary and Transplant Surgery.
Orgullosamente @incmnszmx